Agenus (AGEN) Expected to Post Quarterly Earnings on Thursday

Agenus (NASDAQ:AGEN) will likely be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Agenus to announce earnings of $0.02 per share and revenue of $28.19 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:30 AM ET.

Agenus (NASDAQ:AGEN) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. The company had revenue of $34.52 million for the quarter, compared to analysts’ expectations of $34.00 million. On average, analysts expect Agenus to post ($0.30) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Agenus Price Performance

Shares of AGEN opened at $6.67 on Wednesday. Agenus has a 1-year low of $2.71 and a 1-year high of $10.31. The stock has a market cap of $301.22 million, a PE ratio of 2.59 and a beta of 1.53. The firm has a 50-day simple moving average of $7.54 and a two-hundred day simple moving average of $4.96.

Analyst Ratings Changes

A number of research firms recently weighed in on AGEN. Wall Street Zen cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Rodman & Renshaw started coverage on Agenus in a research report on Monday, September 28th. They set a “buy” rating and a $19.00 price target for the company. Chardan Capital reaffirmed a “buy” rating on shares of Agenus in a research note on Thursday, October 22nd. Finally, B. Riley Financial reiterated a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Agenus Company Profile

Agenus Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.

Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011.